FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., updating the labeling and/or indications for this antiepileptic drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial-onset Seizures

Drugs mentioned

• Vimpat (lacosamide)

Snippet

SUPPL AP for VIMPAT (LACOSAMIDE)